Instillation therapy in superficial urinary bladder cancer. Finnbladder Group.
Carcinoma in situ (TIS) is a special dilemma. Controversial diagnostic and therapeutic attitudes prevail in the literature. Mild dysplasia grade 1 seems to be a condition where 'wait-and-see policy' might be justified according to our series of 60 patients with a TIS whereas, both the TISG2 and TISG3 are real malignancies which need a more aggressive treatment than a transurethral resection (TUR) alone. Under a close control, intravesical chemo- and immunotherapy offer an alternative to cystectomy. On the other hand, for a visible superficial (Ta-T1) cancer TUR is the principal treatment, which can easily be repeated. Anyhow, the high frequency of recurring tumours and the tendency to simultaneous progression in a specific category of patients have led to adJuvant prophylactic treatments. Currently, both intravesical cytostatics and intravesical bacillus Calmette-Guérin have been proven safe with much the same effect. Adjuvant prophylaxis of a primary, single superficial tumour is not indicated, even though the treatment of T1G3 cancer is under discussion.
Jauhiainen
K E
KE
Department of Surgery, Mikkeli Central Hospital, Finland.
Alfthan
O S
OS
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*
D001500:BCG Vaccine; D016685:Mitomycin